Page 1

November 10 , 2021 SUTRO BIOPHARMA Sutro Biopharma Reports Third Quarter 2021 Financial Results , Business Highlights , and Anticipated 2021 Milestones - Patient enrollment has been completed for the STRO - 002 Phase 1 ovarian cancer dose - expansion cohort , and an interim data update is expected in the second half of 2021 - - STRO - 001 Phase 1 dose escalation for non - Hodgkin's lymphoma and multiple myeloma is ongoing to achieve a recommended Phase 2 dose - - Cash , cash equivalents and marketable securities totaled $ 254.2 million as of September 30 , 2021 , with projected cash runway into the second half of 2023 - SOUTH SAN FRANCISCO , Calif . , Nov. 10 , 2021 / PRNewswire / -- Sutro Biopharma , Inc. ( NASDAQ : STRO ) , a clinical - stage drug discovery , development and manufacturing company focused on the application of precise protein engineering and rational design to create next - generation cancer and autoimmune therapeutics , today reported its financial results for the quarter ended September 30 , 2021 , its recent business highlights , and a preview of anticipated select milestones in the remainder of 2021 . " We are pleased to announce that enrollment has been completed for the STRO - 002 Phase 1 dose - expansion cohort for patients with advanced ovarian cancer . Additionally , we are prioritizing the STRO - 002 franchise through additional studies , given the potential for this to be an important treatment option for patients with FolRa - expressing tumors , " said Bill Newell , Sutro's Chief Executive Officer . " For our STRO - 001 program , we continue with dose escalation to achieve a recommended Phase 2 dose and support the work of our partner , BioNova , in Greater China , to explore the therapeutic potential in less heavily pretreated patients with multiple myeloma , non - Hodgkin's lymphoma , and acute myeloid leukemia . " Recent Business Highlights and Anticipated 2021 Select Milestones STRO - 002 , FolRa - Targeting Antibody - Drug Conjugate ( ADC ) : STRO - 002 is being studied in patients with ovarian cancer and endometrial cancer . • The patient enrollment of 40 patients has been completed for the Phase 1 dose- expansion cohort for advanced ovarian cancer , with participation from clinical sites across the U.S. and in Spain .